Pioneering the Future of Metabolic Medicine

For over a decade, MetaboMedica has been at the forefront of developing innovative peptide therapies and metabolic solutions for healthcare professionals worldwide.

0
Years in Metabolic Research
0
Clinicians Trust Our Solutions
0
Countries Served
0
Patents Held
OUR JOURNEY

From Vision to Global Impact

2010

Foundation of MetaboMedica

Founded by Dr. Sarah Johnson and Dr. Michael Chen, two endocrinologists who saw the potential of peptide therapies in metabolic disorders. Established our first research facility in Boston, MA with a team of 8 scientists.

2013

Breakthrough in Peptide Stabilization

Developed proprietary peptide stabilization technology that extended therapeutic half-life by 300%. This innovation became the foundation for our future formulations.

2015

First FDA Approval

Received FDA approval for our first metabolic therapy, establishing MetaboMedica as a serious player in pharmaceutical development.

2018

Global Expansion

Opened European headquarters in Berlin and Asian operations center in Singapore. Partnered with 12 leading research universities worldwide.

2021

Metabolic Health Initiative

Launched our $50 million initiative to combat metabolic syndrome globally, funding 37 clinical studies across 15 countries.

2023

Next-Gen Therapeutics

Entered Phase 3 trials for our revolutionary triple-agonist peptide, representing the most advanced metabolic therapy in development.

OUR LEADERSHIP

World-Class Scientific Minds

Our executive team combines decades of pharmaceutical expertise with cutting-edge metabolic research.

Dr. Michael Chen

Dr. Michael Chen

Co-Founder & Chief Scientific Officer

Former Harvard Medical School researcher with 47 published papers on peptide therapeutics. Pioneer in GLP-1 receptor modulation.

MD, PhD (Endocrinology) Board Certified in Internal Medicine
Dr. Sarah Johnson

Dr. Sarah Johnson

Co-Founder & Chief Medical Officer

Leading authority on metabolic syndrome with 25 years clinical experience. Developed novel protocols for peptide administration.

MD (Internal Medicine) Fellow of the American College of Physicians
Dr. Rajiv Singh

Dr. Rajiv Singh

VP of Research & Development

Former Pfizer executive specializing in peptide drug delivery systems. Holds 14 patents in pharmaceutical formulations.

PhD (Pharmaceutical Sciences) MBA (Healthcare Management)
Dr. James Petrov

Dr. James Petrov

Director of Clinical Affairs

International expert in metabolic clinical trials with experience across 3 continents. Spearheads our global research initiatives.

MD, MSc (Clinical Research) Certified Physician Investigator

Scientific Advisory Board

Dr. Michael Yoshida

Endocrinology, UCSF

Dr. Sarah El-Haddad

Peptide Chemistry, MIT

Dr. James Woolford

Metabolic Research, Oxford

Dr. Lisa Chen

Obesity Medicine, Johns Hopkins

Dr. Henrik Bergström

Regulatory Affairs, Karolinska

OUR FACILITIES

State-of-the-Art Research & Production

Boston Research Headquarters

  • 25,000 sq ft dedicated research space
  • Class 100 clean rooms
  • Automated peptide synthesis systems
  • ISO 9001:2015 certified laboratories

Our flagship facility houses the most advanced peptide research equipment in North America, including cryo-EM for structural analysis and robotic high-throughput screening.

Berlin Manufacturing Center

  • cGMP compliant production
  • EU-wide distribution hub
  • EMA approved facility
  • 98% purity guarantee

Our European center combines German engineering precision with pharmaceutical excellence to produce therapies meeting the strictest international standards.

Singapore Clinical Hub

  • Phase 1-3 trial capabilities
  • Genetic research division
  • APAC regulatory expertise
  • 150-bed research hospital

Strategically located in Asia's medical research corridor, this facility accelerates our global clinical trials and personalized medicine initiatives.

OUR STANDARDS

Uncompromising Quality & Safety

Regulatory Excellence

  • FDA, EMA, and PMDA approved facilities
  • 21 CFR Part 11 compliant systems
  • Rigorous internal audits
  • Complete documentation trails

Analytical Testing

  • HPLC purity verification
  • Mass spectrometry analysis
  • Residual solvent testing
  • Endotoxin screening

Safety Protocols

  • Adverse event monitoring
  • Stability testing programs
  • Cold chain logistics
  • Serialization tracking

Continuous Improvement

  • Six Sigma processes
  • Real-time monitoring
  • Process validation
  • Technology upgrades
OUR REACH

Transforming Metabolic Care Worldwide

Global Presence
37
Countries with Approved Therapies
142
Clinical Trials Conducted
2.1M+
Patients Treated
48
Research Partnerships

Hear From Our Partners

"MetaboMedica's innovative approach to peptide therapies has transformed our diabetes management protocols. Their scientific rigor and commitment to quality set them apart in the field."

Dr. Alejandro Gutierrez Chief of Endocrinology, Madrid University Hospital

"In 15 years of metabolic research, I've never worked with a company so dedicated to both scientific excellence and real-world clinical impact. Their compounds consistently exceed our purity standards."

Prof. Eleanor Chang Director, Singapore Metabolic Institute

"The educational resources and clinical support MetaboMedica provides have been invaluable for our practice. They're not just suppliers - they're true partners in patient care."

Dr. Marcus Johnson Obesity Medicine Specialist, Chicago
OUR FUTURE

Advancing the Frontiers of Metabolic Science

2025-2030 Strategic Initiatives

As we look to the next decade, MetaboMedica is investing $300 million in three transformative areas of metabolic health:

Personalized Peptide Therapies

Leveraging AI and genetic profiling to develop customized treatment regimens based on individual metabolic profiles and biomarker signatures.

Neuro-Metabolic Connections

Pioneering research into the gut-brain axis and its role in metabolic disorders, with novel peptide compounds targeting neurological pathways.

Global Access Programs

Expanding our commitment to underserved populations through tiered pricing, local manufacturing partnerships, and telemedicine support.